IMEX   05356
INSTITUTO DE MEDICINA EXPERIMENTAL
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Levels of the anticoagulant and anti-inflammatory protein S (PROS1) in patients with inflammatory bowel disease (IBD) relationship with disease activity, IBD disease patterns, and C4-binding protein (C4BP)
Autor/es:
G. DE LARRAÑAGA; L. TESSONE; M. BELLICOSO; P. TIRADO; P. CHAVERO; S. PERES; N. SILVIA; S. GONCALVES; C. ROTHLIN; A. SAMBUELLI; A. ERRASTI; S. NEGREIRA; S. HUERNOS; E.A. CARRERA SILVA
Lugar:
Viena
Reunión:
Congreso; 13th Congress of ECCO.; 2018
Institución organizadora:
The European Crohn's and Colitis Organisation (ECCO)
Resumen:
<!-- /* Font Definitions */@font-face{font-family:Times;panose-1:2 0 5 0 0 0 0 0 0 0;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:3 0 0 0 1 0;}@font-face{font-family:"MS 明朝";panose-1:0 0 0 0 0 0 0 0 0 0;mso-font-charset:128;mso-generic-font-family:roman;mso-font-format:other;mso-font-pitch:fixed;mso-font-signature:1 134676480 16 0 131072 0;}@font-face{font-family:"MS 明朝";panose-1:0 0 0 0 0 0 0 0 0 0;mso-font-charset:128;mso-generic-font-family:roman;mso-font-format:other;mso-font-pitch:fixed;mso-font-signature:1 134676480 16 0 131072 0;}@font-face{font-family:Cambria;panose-1:2 4 5 3 5 4 6 3 2 4;mso-font-charset:0;mso-generic-font-family:auto;mso-font-pitch:variable;mso-font-signature:-536870145 1073743103 0 0 415 0;} /* Style Definitions */p.MsoNormal, li.MsoNormal, div.MsoNormal{mso-style-unhide:no;mso-style-qformat:yes;mso-style-parent:"";margin:0in;margin-bottom:.0001pt;mso-pagination:widow-orphan;font-size:12.0pt;font-family:Cambria;mso-ascii-font-family:Cambria;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:"MS 明朝";mso-fareast-theme-font:minor-fareast;mso-hansi-font-family:Cambria;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;}.MsoChpDefault{mso-style-type:export-only;mso-default-props:yes;font-family:Cambria;mso-ascii-font-family:Cambria;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:"MS 明朝";mso-fareast-theme-font:minor-fareast;mso-hansi-font-family:Cambria;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;}@page WordSection1{size:8.5in 11.0in;margin:1.0in 1.25in 1.0in 1.25in;mso-header-margin:.5in;mso-footer-margin:.5in;mso-paper-source:0;}div.WordSection1{page:WordSection1;}-->BackgroundInflammatorybowel diseases (IBD), ulcerative colitis (UC) and Crohn?s disease (CD) show anincreased risk of thrombosis. PROS1 is a well-established anticoagulant. PlasmaPROS1 circulates in a free form that can function as an anticoagulant or incomplex with the complement C4b-binding protein (C4BP). Interestingly, PROS1has also emerged as a potent anti-inflammatory mediator due to its function asagonist of the TAM receptor tyrosine kinases (Rothlin 2015). Here, we aimed totest if IBD or subsets of IBD are associated with reduced amounts of theanticoagulant and anti-inflammatory protein, PROS1. AIMS: to measure andcompare free PROS1 and total C4BP levels in CD, UC and healthy controls andtheir relationship with activity status (Determined for indexes: CDAI, Mayo)and disease patterns (Montreal).MethodsFree PROS1 andC4BP (immunoturburbimetry, Liatest, Stago, France) were determined in 103 IBDpatients (45 M, 58 F, UC: n = 66, CD n = 37) and 30 healthy controls (18 M, 12F), mean ages: 37.5 ± 15.6, 41.4 ± 14.6, 38.2 ± 12.2, respectively.ResultsMean PROS1levels in CD (89.9. ± 28.0) were significantly lower compared with controls(109.6 ± 23.9, p = 0.0019) and UC (104.4 ± 27.0, p = 0.0076). Within the CDgroup, a statistical difference vs. controls was observed in patients withactive disease (n = 25, levels 84.9 ± 24.1, p = 0.0004), but not in patients inremission (n = 12: 100.2 ± 33.5). Moreover, the moderate?severe subset (n =21), presented the lowest levels (84.0 ± 25.9) vs. controls p = 0.0006. In UC,PROS1 levels did not show differences between subsets (42 active, 24 remission:101.1 ± 26.3 and 110.0 ± 27, respectively) or with controls. CD patterns(behaviour, location) and UC extent (12 proctitis, 54 more extensive) did notshow significant differences. C4BP levels were also found to be decreased in CD(global sample, active patients, severe-moderate subsets: 98.6 ± 14.4, 98.8 ±12.0, 98.4 ± 12.6, 109.9 ± 8.8, p = 0.0004, p = 0.0008, p = 0.0014 vs.controls, respectively). Unlike PROS1, C4BP in UC (102.8 ± 9.9) was lower thanin controls (p = 0.0010) mainly in severe?moderate activity (p = 0.0322), and besides,no statistical differences were observed between UC and CD.Conclusion(1) Free PROS1levels were significantly lower in active CD vs. controls (especially in thesevere?moderate activity subsets), but in the case of UC the levels wereindistinguishable from controls. On contrary, C4BP levels were reduced in bothdiseases, particularly in patients with higher disease activity. (2) Decreaseof Free PROS1 in CD, was not secondary to a potential C4BP-bound PROS1 for C4BPincrease. (3) Future studies will aim to test if reduced levels of PROS1 incirculation might not only contribute to the increased risk of thrombosis butalso to the enhanced inflammation in CD.